Ritalin may improve Parkinson's symptoms, OHSU study says

May 06, 2004

PORTLAND, Ore. - A well-known drug used to treat hyperactive children boosts the potency of another drug that reduces Parkinson's disease symptoms, an Oregon Health & Science University study has found.

Scientists at the OHSU Parkinson Center of Oregon found that methylphenidate, known commercially as Ritalin, bolsters the effects of levodopa, a drug converted in the brain to dopamine. Methylphenidate inhibits the reabsorption of dopamine into nerve cells, increasing the neurotransmitter's potency.

Parkinson's disease is caused by a deficiency of nerve cells that produce dopamine.

A parallel study by Parkinson center researchers found that paroxetine, a popular antidepressant best known under the brand name Paxil, doesn't augment the effects of levodopa and has little benefit in reducing physical symptoms of Parkinson's disease.

Paroxetine is a selective serotonin reuptake inhibitor, or SSRI, a class of antidepressants that block the reabsorption of another neurotransmitter, serotonin, into nerve cells. Researchers studied it because laboratory evidence has suggested the serotonin transporter, the system through which serotonin is reabsorbed into nerve cells, may take up dopamine as well.

"Both studies looked at the effects of these drugs on Parkinson's disease," said John "Jay" G. Nutt, M.D., professor of neurology, and physiology and pharmacology, OHSU School of Medicine, and director of the Parkinson center. He also is director of the Parkinson's Disease Research, Education, and Clinical Center (PADRECC) at the Portland Veterans Affairs Medical Center. The studies were presented last week at the 56th annual meeting of the American Academy of Neurology in San Francisco.

Ritalin, the drug used in the methylphenidate study, "increases the effects of levodopa," Nutt said, while paroxetine didn't affect Parkinson's disease symptoms. However, paroxetine, when taken without levodopa, did increase the walking speed of Parkinson's patients.

"There was no evidence that (paroxetine) made Parkinson's disease worse, as some clinicians have suggested," Nutt said. "If that occurred, it probably wasn't by negatively impacting dopamine's effects."

In the Ritalin study, 14 Parkinson's disease patients with fluctuating responses to levodopa were examined. All received two-hour levodopa infusions at either minimum or maximum doses for four consecutive days, but some also received oral doses of Ritalin. Participants were then tested for symptoms of Parkinsonism, including tapping and walking speeds; dyskinesia or involuntary movements such as twitching, nodding and jerking; mood, anxiety and fatigue; and sitting blood pressure.

Ritalin amplified the effects of levodopa, particularly for those given minimum doses of levodopa. It increased, from 36 percent to 86 percent, the number of patients responding to levodopa, and it boosted the duration of levodopa response as measured by tapping and walking tests. But the severity of dyskinesia, a side effect of levodopa therapy, did not rise.

In addition, Ritalin decreased another levodopa side effect - hypotension, or low blood pressure - and it enhanced improvements levodopa made in mood and decreased fatigue. Adverse effects, in general, were minimal, and the drug had no effect when given alone to Parkinson's disease patients.

The study's findings do more than show that Ritalin improves patients' responses to levodopa, Nutt said. They confirm the importance of the dopamine transporter, the system through which dopamine is reabsorbed into nerve cells, and shows that the transporter may be a target for other levodopa-boosting drugs.

"It may be that by blocking the dopamine transporter with one drug or another, we can augment the effects of levodopa and get better control of Parkinson's disease," he said.

Pharmaceutical companies already are looking at other drugs that may block the transporter, Nutt added. And the OHSU Parkinson Center will continue to study Ritalin, including whether more doses promotes levodopa response throughout the day.

"The first study is proof of principle - blocking the dopamine transporter," Nutt said. "Now the question is, would Ritalin be the drug to do that? That's not clear."

The paroxetine study was conducted on 14 people with varying severity of Parkinson's disease. Each was given two-hour levodopa infusions; some also received paroxetine for two weeks while the rest were given a placebo. The subjects were then scored for tapping rate, tremor and dyskinesia, as well as walking speed.

Paroxetine, when given with levodopa, didn't affect tapping, dyskinesia or tremor, according to the findings. In fact, six people reported worse balance while on paroxetine.

Nutt's Ritalin study collaborators were Julie H. Carter, R.N., A.N.P., associate professor of neurology, OHSU School of Medicine, and associate director of the Parkinson center; and Gary J. Sexton, Ph.D., associate professor of public health and preventive medicine, OHSU School of Medicine. Paroxetine study collaborators were Kathryn A. Chung, M.D., assistant professor of neurology, OHSU School of Medicine and the Parkinson center, and PADRECC, Portland VA Medical Center.
-end-
Both studies were supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health; PADRECC; and the National Parkinson Foundation.

To access all OHSU news releases, visit www.ohsu.edu/news/

Oregon Health & Science University

Related Dopamine Articles from Brightsurf:

Dopamine surge reveals how even for mice, 'there's no place like home'
''There's no place like home,'' has its roots deep in the brain.

New dopamine sensors could help unlock the mysteries of brain chemistry
In 2018, Tian Lab at UC Davis Health developed dLight1, a single fluorescent protein-based biosensor.

Highly sensitive dopamine detector uses 2D materials
A supersensitive dopamine detector can help in the early diagnosis of several disorders that result in too much or too little dopamine, according to a group led by Penn State and including Rensselaer Polytechnic Institute and universities in China and Japan.

Dopamine neurons mull over your options
Researchers at the University of Tsukuba have found that dopamine neurons in the brain can represent the decision-making process when making economic choices.

Viewing dopamine receptors in their native habitat
A new study led by UT Southwestern researchers reveals the structure of the active form of one type of dopamine receptor, known as D2, embedded in a phospholipid membrane.

Significant differences exist among neurons expressing dopamine receptors
An international collaboration, which included the involvement of the research team from the Institut de Neurociències of the UAB (INC-UAB), has shown that neurons expressing dopamine D2 receptors have different molecular features and functions, depending on their anatomical localization within the striatum.

How dopamine drives brain activity
Using a specialized magnetic resonance imaging (MRI) sensor that can track dopamine levels, MIT neuroscientists have discovered how dopamine released deep within the brain influences distant brain regions.

Novelty speeds up learning thanks to dopamine activation
Brain scientists led by Sebastian Haesler (NERF, empowered by IMEC, KU Leuven and VIB) have identified a causal mechanism of how novel stimuli promote learning.

Evidence in mice that childhood asthma is influenced by the neurotransmitter dopamine
Neurons that produce the neurotransmitter dopamine communicate with T cells to enhance allergic inflammation in the lungs of young mice but not older mice, researchers report Nov.

Chronic adversity dampens dopamine production
People exposed to a lifetime of psychosocial adversity may have an impaired ability to produce the dopamine levels needed for coping with acutely stressful situations.

Read More: Dopamine News and Dopamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.